Versant Ventures Looks To Canada, Europe For New Deals
This article was originally published in Start Up
Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”
You may also be interested in...
Reinventing Flexion For The World Beyond Proof-Of-Concept
Flexion Therapeutics had the pedigree, determination, and corporate connections to source and speed to clinical proof-of-concept its in-licensed pharma assets, and it planned to build a business around getting paid to do so. But a funny thing happened on the way to the bank.
Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant
The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.
BMS' Purchase Of Amira: When An Acquisition Is Really An Asset Sale
Bristol-Myers Squibb Co.'s purchase of Amira Pharmaceuticals Inc. for $325 million upfront and another $150 million in downstream milestones shows that prior licensing deals and multiple programs in a pipeline don't necessarily curb a start-up's acquisition potential, provided investors are thinking smartly about deal structures that create separate value streams for the various products in the portfolio.